sulfasalazine has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We observed previously established medical associations for MND and an inverse dose-response association between lovastatin and MND, with 28% reduced risk at 40 mg/day." | 1.91 | Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model. ( Kreple, CJ; Miller, TM; Racette, BA; Schoch, KM; Searles Nielsen, S; Shabsovich, M; Shen, T; Song, Y, 2023) |
| " We examined the possibility that concurrent blockade of free radicals and prostaglandin E(2) (PGE(2))-mediated inflammation might constitute a safe and effective therapeutic approach to ALS." | 1.38 | Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. ( Cho, W; Gwag, BJ; Im, DS; Lee, JH; Lee, JK; Lee, YA; Lee, YB; Shin, JH; Springer, JE; Yun, BS, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kreple, CJ | 1 |
| Searles Nielsen, S | 1 |
| Schoch, KM | 1 |
| Shen, T | 1 |
| Shabsovich, M | 1 |
| Song, Y | 1 |
| Racette, BA | 1 |
| Miller, TM | 1 |
| Shin, JH | 1 |
| Lee, YA | 1 |
| Lee, JK | 1 |
| Lee, YB | 1 |
| Cho, W | 1 |
| Im, DS | 1 |
| Lee, JH | 1 |
| Yun, BS | 1 |
| Springer, JE | 1 |
| Gwag, BJ | 1 |
| Clement, AM | 1 |
3 other studies available for sulfasalazine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model.
Topics: Aged; Amyotrophic Lateral Sclerosis; Animals; Case-Control Studies; Disease Models, Animal; Humans; | 2023 |
Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Anti-Infl | 2012 |
Two in one against motor neuron degeneration: tackling oxidative stress and inflammation with a sulfasalazine derivative.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Free | 2012 |